NASDAQ$SION
Sionna Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
Sionna Therapeutics reported Q3 2025 revenue of $1.0M, a net loss of $20.3M.
For Q3 2025, Sionna Therapeutics reported Revenue was $1.0M, net loss was $20.3M. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Revenue $1.0M for Q3 2025.
- Net loss $20.3M.
- MD&A covers liquidity, capital allocation, and sector-specific risks.
Headline financials
Revenue & EPS history
Sionna Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Collaboration, licensing, or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q3 2025
-0.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+15.4%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+13.4%
Q2 2025
Best reaction
-11.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -11.3% | -12.4% | -21.8% | |
| Q4 2025 | -7.2% | -1.7% | +13.0% | |
| Q3 2025 | -1.6% | +0.4% | +13.0% | |
| Q2 2025 | +13.4% | +17.8% | +32.8% | |
| Q1 2025 | +4.7% | +9.0% | +40.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro